Timothy Edward Lee Sells 19,663 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Timothy Edward Lee sold 19,663 shares of Invivyd stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $1.54, for a total value of $30,281.02. Following the transaction, the insider owned 138,681 shares in the company, valued at approximately $213,568.74. This trade represents a 12.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Timothy Edward Lee also recently made the following trade(s):

• On Wednesday, February 18th, Timothy Edward Lee sold 20,964 shares of Invivyd stock. The stock was sold at an average price of $1.58, for a total value of $33,123.12.

Invivyd Stock Down 2.4%

Shares of Invivyd stock opened at $1.61 on Friday. The business has a fifty day simple moving average of $2.17 and a 200-day simple moving average of $1.75. Invivyd, Inc. has a fifty-two week low of $0.46 and a fifty-two week high of $3.07. The firm has a market cap of $375.32 million, a price-to-earnings ratio of -3.43 and a beta of 0.60.

Analyst Upgrades and Downgrades

IVVD has been the subject of several research reports. HC Wainwright raised their price objective on shares of Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Invivyd in a report on Monday, December 29th. D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. Finally, BTIG Research reiterated a “buy” rating on shares of Invivyd in a research report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.00.

Institutional Investors Weigh In On Invivyd

Hedge funds have recently made changes to their positions in the company. Courier Capital LLC acquired a new position in Invivyd in the 4th quarter worth approximately $25,000. Bronte Capital Management Pty Ltd. acquired a new stake in Invivyd during the 4th quarter valued at $27,000. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Invivyd in the second quarter valued at $27,000. DRW Securities LLC purchased a new stake in shares of Invivyd in the fourth quarter valued at $27,000. Finally, Vanguard Personalized Indexing Management LLC boosted its position in shares of Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after buying an additional 28,146 shares during the period. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.